Agilent to Acquire Biocare Medical for $950M, Expanding Pathology Portfolio — Agilent Technologies, Inc.

Event summary

Agilent Technologies Inc. to acquire Biocare Medical in an all-cash transaction valued at $950 million.
Biocare Medical generated over $90 million in revenue in 2025 and has achieved annual double-digit revenue and profit growth since 2021.
The acquisition is expected to close by no later than Agilent's fourth fiscal quarter of 2026.
Biocare will become part of the Agilent Life Sciences and Diagnostics Markets Group upon close.
The deal is expected to be accretive to Agilent’s top-line growth rate, margin profile, and non-instrument revenue mix in the first year.

The big picture

Agilent’s acquisition of Biocare Medical aligns with its strategy to drive long-term growth through customer-centric innovation and disciplined capital allocation. The deal expands Agilent’s pathology portfolio, enhancing its ability to serve a broad range of pathology labs across clinical and research settings. This move comes amid a broader trend of consolidation in the diagnostics and life sciences tools sector, as companies seek to strengthen their offerings and market reach.

What we're watching

Integration Challenges: How Agilent will manage the integration of Biocare’s operations and whether it can achieve expected synergies within the expected timeframes.
Market Expansion: The pace at which Agilent can leverage Biocare’s strong U.S. commercial presence to expand its global operations.
Regulatory Approvals: Whether the transaction will receive all required regulatory approvals and close by the expected date.